Amylin Pharmaceuticals Inc. and Eli Lilly and Co. said Nov. 8 that they are ending their long-standing partnership to develop and market a medication for treating type 2 diabetes mellitus.
In addition, the companies said they would settle outstanding litigation over whether Lilly’s sales of Byetta (exenatide)—while it also was selling a competing diabetes drug, Boehringer Ingelheim’s Tradjenta (linagliptin)—breached the parties’ collaborative agreement to develop a once-weekly version of exenatide.
Byetta is an injectable diabetes drug, and is sold in multiple-dose, pre-filled pens for use with a primary treatment to improve glycemic control in patients with type 2 diabetes. Tradjenta, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.